---
schema_version: "secwatch.filing_event.v1"
accession: "0001703057-26-000010"
form_type: "8-K"
ticker: "ABCL"
cik: "0001703057"
company_name: "AbCellera Biologics Inc."
filed_at: "2026-02-24T23:59:59+00:00"
generated_at: "2026-05-16T00:50:22.373080+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AbCellera FY2025 revenue $75.1M, net loss $146.4M; liquidity ~$700M

## Summary
- Revenue $75.1M vs $28.8M YoY; net loss $146.4M vs $162.9M; EPS $(0.49) vs $(0.55).
- Available liquidity ~$700M ($561M cash + $135M non-dilutive govt funding).
- Advanced ABCL635 into Phase 2, ABCL575 in Phase 1; two candidates into IND/CTA-enabling.
- Cumulative partner programs 104 (+8), molecules in clinic 19 (+3).
- Appointed Sarah Noonberg, M.D., Ph.D. as Chief Medical Officer.

## SEC filing metadata
- accession: 0001703057-26-000010
- form_type: 8-K
- ticker: ABCL
- cik: 0001703057
- company_name: AbCellera Biologics Inc.
- filed_at: 2026-02-24T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000010/0001703057-26-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703057/000170305726000010/abcl-20260224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001703057-26-000010
- JSON: https://secwatch.observer/filing/0001703057-26-000010.json
- Plain text: https://secwatch.observer/filing/0001703057-26-000010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.